New dye could help spot celiac disease during endoscopy
NCT ID NCT07377565
First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 4 times
Summary
This early study tests a single oral dose of HB-2121 in 20 adults with suspected celiac disease. The dye is given four hours before a standard endoscopy to see how it interacts with the small intestine and whether it is safe. Researchers will track side effects and measure the dye's brightness in biopsy samples for up to 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HB-2121
- What this could lead to
- If successful, HB-2121 could become a new diagnostic tool to help doctors identify celiac disease more easily during routine endoscopy.
- What could go wrong
- This is a very early Phase 1 safety study with only 20 participants. It is not designed to prove the diagnostic works, only that it is safe. Many early-stage trials do not lead to approved tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lesson in Gluten-Free eating boost Kids' health?
- Wheat sensitivity linked to fatty liver? a new study investigates
- Blood test plus symptom check may spare thousands from celiac biopsy
- Iron infusions may boost gut healing in celiac disease
- Massive spanish study maps celiac disease trends across generations
- Can a home gluten test help heal celiac disease?